SEATTLE, Dec. 1, 2016 /PRNewswire/ -- CTI BioPharma
Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced the
results of a translational pharmacology study comparing biomarker
activity profiles for three JAK inhibitors: pacritinib,
ruxolitinib and momelotinib, using the BioMAP® Diversity
PLUS panel of in vitro human primary cell-based systems. The
results demonstrated distinct profiles amongst these JAK inhibitors
and suggest that clinical responses are likely to be distinct with
each agent. The results were presented at the EORTC-NCI-AACR
Molecular Targets and Cancer Therapeutics Symposium, November 29 - December 2 in Munich, Germany.
At clinically relevant concentrations, each of the JAK
inhibitors reduced inflammatory mediators associated with
myelofibrosis such as TNF and IL-6, however they had divergent
effects on other immunological and inflammatory pathways. When
tested on human lymphoid cells, pacritinib had the strongest
inhibitory activities on sIL-17A, sIL-2 and sIL-6, mediators
involved in autoimmune responses, while ruxolitinib had the broader
inhibitory activities in multiple systems. Both ruxolitinib and
pacritinib were inhibitory to B cells, but
only ruxolitinib inhibited T cells that are associated with
cell-mediated immunity. Only pacritinib was anti-proliferative
to endothelial cells and fibroblasts, effects commonly seen in
agents with anti-cancer properties. The resulting distinct
phenotypic profiles of pacritinib, ruxolitinib and momelotinib,
illustrate that although all were developed as JAK2-ATP binding
site inhibitors, they have divergent biological effects and likely
will have distinct clinical activities.
The poster for Abstract #P094: "Comparative Biomarker Profiles
of Pacrtitinib, Momelotinib, Pexidartinib and Ruxolitinib Using
BIOMAP® Diversity Plus Panel" is available
at www.ctibiopharma.com.
About Pacritinib
Pacritinib is an investigational oral kinase inhibitor with
specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of
enzymes is a central component in signal transduction pathways,
which are critical to normal blood cell growth and development, as
well as inflammatory cytokine expression and immune responses.
Mutations in these kinases have been shown to be directly related
to the development of a variety of blood-related cancers, including
myeloproliferative neoplasms, leukemia and lymphoma. In addition to
myelofibrosis, the kinase profile of pacritinib suggests its
potential therapeutic utility in conditions such as acute myeloid
leukemia, or AML, myelodysplastic syndrome, or MDS, chronic
myelomonocytic leukemia, or CMML, and chronic lymphocytic leukemia,
or CLL, due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on
the acquisition, development and commercialization of novel
targeted therapies covering a spectrum of blood-related cancers
that offer a unique benefit to patients and healthcare providers.
CTI BioPharma has a commercial presence in Europe with respect to PIXUVRI® and
a late-stage development pipeline, including pacritinib for the
treatment of patients with myelofibrosis. CTI BioPharma is
headquartered in Seattle,
Washington, with offices in London and Milan under the name CTI Life Sciences
Limited. For additional information and to sign up for email alerts
and get RSS feeds, please visit www.ctibiopharma.com.
Forward-Looking Statements
This press release includes forward-looking statements, which
are within the meaning of the Safe Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to a number of risks and uncertainties, the outcome of
which could materially and/or adversely affect actual future
results and the trading price of the issuers' securities. Such
statements include, but are not limited to expectations with
respect to the potential therapeutic utility of pacritinib.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release. The statements are based on assumptions about many
important factors and information currently available to us to the
extent we have thus far had an opportunity to fully and carefully
evaluate such information in light of all surrounding facts,
circumstances, recommendations and analyses. A number of results
and uncertainties could cause actual results to differ materially
from those in the forward-looking statements, including:
satisfaction of regulatory and other requirements; that trial
results observed to date may differ from future results or that
different conclusions or considerations may qualify such results
once existing data has been more fully evaluated; actions of
regulatory bodies and other governmental authorities; other
clinical trial results; changes in laws and regulations; product
quality, product efficacy, study protocol, data integrity or
patient safety issues; product development risks; and other risks
identified in each of the issuer's most recent filings on Forms
10-K and 10-Q and other Securities and Exchange Commission filings.
Except as required by law, CTI BioPharma does not intend to update
any of the statements in this press release upon further
developments.
CTI BioPharma Contact:
Ed Bell
+1 206-272-4345
ebell@ctibiopharma.com
Logo - http://photos.prnewswire.com/prnh/20140529/92480
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cti-biopharma-presents-nonclinical-pharmacology-study-demonstrating-pacritinib-has-distinct-profile-amongst-jak-inhibitors-at-eortc-nci-aacr-molecular-targets-and-cancer-therapeutics-symposium-300371716.html
SOURCE CTI BioPharma Corp.